Quote | SAB Biotherapeutics Inc. Warrant (NASDAQ:SABSW)
Last: | $0.025 |
---|---|
Change Percent: | 21.75% |
Open: | $0.0313 |
Close: | $0.025 |
High: | $0.0313 |
Low: | $0.01 |
Volume: | 21,640 |
Last Trade Date Time: | 05/14/2024 03:00:00 am |
News | SAB Biotherapeutics Inc. Warrant (NASDAQ:SABSW)
MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progres...
MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIg...
Message Board Posts | SAB Biotherapeutics Inc. Warrant (NASDAQ:SABSW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
SAB Biotherapeutics Inc. Warrant Company Name:
SABSW Stock Symbol:
NASDAQ Market:
MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company w...
MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progres...
MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIg...